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mismatched related (MRD) donors have increased the incidence of
CMV infection and disease. Methods: Twenty-four (24) out of 50
patients have been enrolled into a prospective trial evaluating the
safety and efﬁcacy of valganciclovir for the early prophylaxis of
CMV infection. Patients are either CMV seropositive or CMV
seronegative receiving CMV seropositive stem cell products. Other
inclusion/exclusion criteria include estimated creatinine clearance
of  50 mL/min, platelet count  50,000/L, and WBC count 
1,000/L. Patients receive valganciclovir at 900 mg daily Mondays
through Fridays starting 21–35 days after transplantation and con-
tinuing through posttransplantation day 100, with dosage adjust-
ments for myelosuppression and/or reduced creatinine clearance.
Patients are monitored with weekly CMV PCR analysis performed
at a central laboratory. Results: All patients were CMV seropos-
itive at the time of transplant. Donors included 15 MRD and 9
MUD. Stem cell sources included 21 peripheral blood and 3 bone
marrow. Seven patients required corticosteroids for treatment of
graft-versus-host disease. Three patients developed myeloid toxic-
ity related to valganciclovir (absolute neutrophil count 1,000/L
in 1 patient and platelets  50,000/L in 2 patients). All 3 patients
recovered their counts and restarted valganciclovir with dosage
adjustments. A total of 11 patients required dosage adjustments due
to myelosuppression (in 3 patients), creatinine clearance (in 4),
weight (in 1), or institutional decision (in 3). CMV infection
occurred in 2 patients; no patients developed CMV disease. The 2
patients with positive CMV-PCR developed infection 1 (day 40)
and 2 (day 36) weeks after starting valganciclovir. These 2 patients
were successfully treated with IV ganciclovir. So far, 10 patients
have been followed between day 100 and 6 months posttrans-
plantation; of these, 3 continued valganciclovir off study. Of these
10 patients, 2 developed CMV infection. Both patients were not
receiving CMV prophylaxis and were successfully treated with
valganciclovir. None of the 3 patients that continued valganciclovir
up to 6 months posttransplantation developed CMV infection.
Survival is 80% (16 of 20) at day 100 and 82% (9 of 11) at 6
months posttransplantation. Conclusions: We conclude that val-
ganciclovir at the dosage used in this study is well tolerated with
minimal reversible myelosuppression. The early prophylaxis and
suppression of CMV viremia correlates favorably with preemptive
strategies.
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PREEMPTIVE THERAPY WITH GANCICLOVIR AND SHORT-COURSE IN-
TRAVENOUS IMMUNOGLOBULIN DOES NOT PREVENT RECURRENT CY-
TOMEGALOVIRUS INFECTION (CBMTG-102 STUDY)
Hasegawa, W.S.4, Pond, G.R.1, Dranitsaris, G.1, Jenkins, G.G.1,
Couban, S.2, Walker, I.R.3, Lipton, J.H.1 1Princess Margaret Hospital/
University Health Network, Toronto, ON, Canada; 2Queen Elizabeth II
Health Sciences Centre, Halifax, NS, Canada; 3McMaster University
Medical Centre, Hamilton, ON, Canada; 4Saskatoon Cancer Centre,
Saskatoon, SK, Canada.
Background: Cytomegalovirus (CMV) infection continues to be
a signiﬁcant problem following allogeneic hematopoietic stem cell
transplantation. Preemptive therapy with ganciclovir (GCV) re-
duces the incidence of CMV disease, but 20%-50% of patients
develop recurrent CMV infection and require further treatment.
Because intravenous immunoglobulin (IVIG) increases CMV an-
tibody titers and has proven beneﬁcial for the treatment of CMV
pneumonitis, we hypothetized that a preemptive regimen with a
short course of IVIG and GCV would reduce the incidence of
recurrent CMV infection. Methods: A 2-stage randomized phase
II multicenter study was conducted with a control arm included to
verify a 50% incidence of recurrent CMV infection. A total of 23
allogeneic myeloablative stem cell transplantation patients with
CMV viremia, detected using CMV antigenemia asssay (in 22
patients) or CMV PCR assay (in 1 patient), were enrolled. Fifteen
patients received IV GCV 5 mg/kg every 12 hours until CMV
viremia had resolved (minimum 14 days) and IVIG 500 mg/kg on
Monday, Wednesday, and Friday for 3 doses. Eight control pa-
tients were randomly selected to receive only GCV. Patients were
followed 6 months for recurrence of CMV infection. An economic
analysis was also performed. Results: The study was stopped after
the interim analysis, because no signiﬁcant decrease in recurrent
CMV infection was observed. The mean age of the 15 study
patients was 37.5 years. Diagnoses were 6 ALL, 3 AML, 2 my-
eloma, 1 MDS, 1 CML, 1 ALL, and 1 NHL. The stem cells were
from peripheral blood (in 12 patients) or bone marrow (in 3
patients), with 80% from HLA-matched donors. Positive CMV
serology was present in 10 donors and 13 recipients pretransplan-
tation. CMV viremia was detected a median of 41 days (range,
26–243 days) posttransplantation. Recurrent CMV viremia has
occurred in 8 of 15 patients (53%). This was similar to the control
arm, in which 3 of 8 patients (43%) developed CMV recurrence
and 1 patient (14%) failed GCV therapy. Acute GVHD occurred
in 73% of patients and chronic GVHD in 83% of patients during
the 6-month study period. Thirteen patients were alive at last
follow-up, and 2 patients had relapsed hematologic disease. The
economic analysis indicates that patients receiving GCV and IVIG
developed more infectious complications requiring hospital admis-
sions, which resulted in a signiﬁcantly higher overall cost compared
to control patients.Conclusions:The addition of a short course of
IVIG to GCV for preemptive therapy of CMV infection does not
reduce the incidence of recurrent CMV infection.
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PHASE I TRIAL OF CG53135-05 TO PREVENT MUCOSITIS IN PATIENTS
UNDERGOING HIGH-DOSE CHEMOTHERAPY (HDCT) AND AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT)
Schuster, M.W.1, Shore, T.B.1, Harpel, J.1, Greenberg, J.1,
Jalilizeinali, B.1, Possley, S.1, Halvorsen, Y.-D.2, Annino, V.I.2,
Hahne, W.2 1The New York Presbyterian Hospital, Weill Cornell Med-
ical Center, New York, NY; 2CuraGen Corporation, Branford, CT.
Mucositis is a painful side effect of many transplantation condi-
tioning regimens and often requires treatment with potent narcotic
pain medications. It may even require intravenous patient-con-
trolled analgesia (PCA) for adequate pain relief, as well as total
parenteral nutrition (TPN). Recently, a new class of drugs in the
ﬁbroblast growth factor (FGF) family has shown promise in more
effectively ameliorating or even preventing oral mucositis (OM).
We report on the results of a phase I trial with CG53135-05, a
novel investigational protein therapeutic (FGF-20) that promotes
epithelial and mesenchymal cell proliferation in vitro and has
demonstrated activity in animal models. A total of 22 patients (age
range, 25–75 years) undergoing HDCT with PBSCT were treated
with escalating doses of study drug, including 0.03 mg/kg in 2
patients, 0.1 mg/kg in 10, 0.2 mg/kg in 8, and 0.33 mg/kg in 2.
Patients were treated for multiple myeloma in 11, non-Hodgkin’s
lymphoma in 9, acute myelogenous leukemia in 1, and desmoplas-
tic round cell tumor in 1 and received conditioning regimens
including melphalan (Mel 200); cyclophosphamide, carmustine,
and etoposide (CBV); carboplatin and thiotepa (CT); and busulfan/
cyclophosphamide (targeted BuCy). The primary objective of the
trial was to evaluate safety, tolerability, and pharmacokinetics of
CG53135-05. Patients were also scored daily for presence of OM.
Among the 22 patients completing the study, 8 patients experi-
enced no OM (including 4 Mel 200 patients), 10 patients experi-
enced only WHO grade 1 (n  7) or grade 2 (n  3) OM, and 4
patients experienced severe OM of grade 3 (n  3) or grade 4 (n 
1). One patient experiencing grade 4 OM required TPN for 4 days.
Patients tolerated the study drug well with no signiﬁcant side
effects up to a dose of 0.33 mg/kg. At that dose, 2 patients expe-
rienced an infusional reaction consisting of fever, nausea, and mild
hypotension. Preliminary pharmacokinetic results from 13 patients
conﬁrmed dose-dependent plasma exposure with an average Cmax
of 135.5 ng/mL at a dose level of 0.1 mg/kg, 343.3 ng/mL at 0.2
mg/kg, and 658.3 ng/mL at 0.33 mg/kg.
CG53135-05 is a member of a breakthtrough drug class (FGF
family) that was well tolerated in PBSCT patients at doses up to
0.33 mg/kg with apparent clinical effects in ameliorating or pre-
venting OM. Thus 18 of 22 patients avoided (WHO grades 3–4)
mucositis following HDCT. A larger phase II clinical trial will be
initiated to evaluate the efﬁcacy of CG53135-05 in preventing
HDCT-induced OM.
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